

**ACHA Webinars Presents:**

## **The Beat Goes On: Rhythm Issues in Adults with CHD**

Wednesday, May 25, 2016, 7 p.m. – 8 p.m. EDT

**Presenter:**

**Jonathan Ginns, MD and Angelo Biviano, MD**

### **About the Webinar**

Are you an adult congenital heart disease (CHD) patient who has arrhythmias or irregular heartbeats? Have you wondered why these occur? Do you know that while arrhythmias in CHD patients are different from rhythm problems in people without CHD, many of the medications and procedures used to treat them are the same? If you have a history of arrhythmias, take medications for them, have had an ablation, or have a pacemaker or ICD, you don't want to miss this webinar. You will learn about the new advances in their management and how they can be successfully treated. Register today.



**REGISTER NOW:**

<https://attendee.gotowebinar.com/register/4324652284790749444>

### **About the Presenter**

Dr. Jonathan Ginns is an adult congenital heart disease cardiologist working at the Schneeweiss Adult Congenital Heart Disease unit at Columbia-New York Presbyterian Hospital. His interests include clinical cardiology and echocardiography; he also reads cardiac MRI and CT and performs diagnostic cardiac catheterizations.

Dr. Angelo Biviano is an electrophysiologist at Columbia-New York Presbyterian and has been involved in the management of rhythm issues in hundreds of ACHD patients. He performs radiofrequency ablation procedures and insertion of pacemakers and implantable defibrillators.

### **About the Adult Congenital Heart Association**

The mission of the Adult Congenital Heart Association (ACHA) is to improve and extend the lives of the millions born with heart defects through education, advocacy and the promotion of research. If you would like to find out more about our programming, visit our website, [www.achaheart.org](http://www.achaheart.org). To support ACHA's mission to improve and prolong the lives of heart defect survivors, you can make a donation on our website.

**This webinar was made possible in part by unrestricted educational grants from Actelion Pharmaceuticals US, Inc. and Gilead Sciences.**